58605-87-1Relevant academic research and scientific papers
METHODS OF TREATMENT WITH AMINOLEVULINIC ACID SYNTHASE 2 (ALAS2) MODULATORS
-
Paragraph 00164, (2020/12/29)
Described herein is a compound of Formula I or a pharmaceutically acceptable salt thereof: wherein Ring A R1, R2, a, b, and n are as defined herein. Also described is a method of treating a subject having a disorder in need of treatment, comprising inhibiting aminolevulinic acid synthase 2 (ALAS2) in the subject by administering a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Disorders that are of particular interest are blood disorders, such as porphyria and anemia.
Acyclic cyanamide-based inhibitors of cathepsin K
Barrett, David G.,Deaton, David N.,Hassell, Anne M.,McFadyen, Robert B.,Miller, Aaron B.,Miller, Larry R.,Payne, J. Alan,Shewchuk, Lisa M.,Willard Jr., Derril H.,Wright, Lois L.
, p. 3039 - 3043 (2007/10/03)
Conversion of the proline-derived cyanamide lead to an acyclic cyanamide capable of forming an additional hydrogen bond with cathepsin K resulted in a large increase in inhibitory activity. An X-ray structure of a co-crystal of a cyanamide with cathepsin K confirmed the enzyme interaction. Furthermore, a representative acyclic cyanamide inhibitor 6r was able to attenuate bone resorption in the rat calvarial model.
Process for the production of 1,2,4-triazole derivatives
-
, (2008/06/13)
Process for the production of 1-alkyl-3-hydroxy-5-chloro-1,2,4-triazoles wherein an alkylhydrazine is reacted in an inert solvent in the presence of an acid binding agent with cyanogen chloride to 1-alkyl-1-cyanohydrazine which is subsequently cyclized with phosgene.
